[Sample Quality Control through the Depository and Distribution of Cancer-Related Human Materials: Experience of Kanagawa Cancer Research & Information Association (KCRIA)].
Kanagawa Prefecture and its department of hospital business established the Kanagawa Cancer Research and Information Association (KCRIA) in 2006, and the Kanagawa Cancer Center (KCC) and related institutes have started to collect and distribute patient-derived cancer-related biomaterials to researchers. The tumor tissue center of KCC is collecting frozen tumor tissues, formalin-fixed and paraffin-embedded (FFPE) tumor tissues, serum of patients before treatment, and genomic DNA of peripheral white blood cells. Corresponding normal tissues are also collected if possible. Clinical information on patients is annotated in each sample as accurately as possible under linkable anonymization to follow the prognosis. We are evaluating the quality of tumor samples with two indices: the RNA Integrity Number (RIN) of extracted total RNAs from randomly chosen frozen tissues examined with the 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA), and the histopathological examination of parts of all frozen tissues prepared in the Optimal Cutting Temperature (OTC) compound and evaluation of the contents of tumor cells. Management of the sample quality is an important issue for any biomaterial repository. The quality of samples is influenced by the procedures of sample collection and storage, and also by the storage duration. The quality could be periodically examined by monitoring analyte stability and integrity, such as RIN of frozen cancer tissues. However, the best way to collect and store RNA might not always be the same for different analytes. Therefore, sample quality control at biomaterial repositories that are preparing samples for future studies on undefined analytes is a very difficult problem. At least the standard sample operation procedure (SOP) should be available for users.